文献速递淋巴瘤

维布妥昔单抗联合化疗治疗III/IV期经典型霍奇金淋巴瘤:ECHELON-1研究3年更新

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
PubMed 文献 · Blood · 2020-01-01

ECHELON-1是一项3期随机研究,纳入1334例III/IV期经典型霍奇金淋巴瘤患者,比较A+AVD与ABVD一线治疗。中位随访37个月,A+AVD的3年PFS率为83.1%,ABVD为76.0%,且在PET2阴性<60岁患者中分别为87.2%与81.0%。A+AVD疗效获益在各亚组一致,周围神经病变多数缓解或改善。

要点

  • A+AVD较ABVD显著改善III/IV期cHL的3年PFS(83.1% vs 76.0%)。
  • PET2阴性<60岁患者3年PFS为87.2% vs 81.0%,PET2阳性者亦见获益趋势。
  • A+AVD获益不依赖疾病分期和预后因素,且无需治疗强化或博来霉素暴露。

核心结论

  • A+AVD一线治疗III/IV期cHL较ABVD提供持久的疗效获益,且在各关键亚组中一致。

研究设计与样本

  • 3期随机对照研究ECHELON-1,共1334例III/IV期cHL患者按1:1随机接受6周期A+AVD(n=664)或ABVD(n=670),要求进行PET2中期评估。

主要发现

  • 中位随访37个月,A+AVD组3年PFS率为83.1%,ABVD组为76.0%。
  • PET2阴性且年龄<60岁患者中,A+AVD组3年PFS率为87.2%,ABVD组为81.0%。
  • PET2阳性且年龄<60岁患者中,A+AVD组3年PFS率为69.2%,ABVD组为54.7%。
  • A+AVD组周围神经病变患者中78%完全缓解或改善,ABVD组为83%。

临床怎么用

  • A+AVD可作为III/IV期cHL的一线治疗选择,无需根据PET2结果进行治疗强化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with doxorubicin, vinblastine, and dacarbazine (AVD; A+AVD) exhibited superior modified progression-free survival (PFS) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for frontline treatment of patients with stage III/IV classical Hodgkin lymphoma (cHL). Maturing positron emission tomography (PET)-adapted trial data highlight potential limitations of PET-adapted approaches, including toxicities with dose intensification and higher-than-expected relapse rates in PET scan after cycle 2 (PET2)-negative (PET2-) patients. We present an update of the ECHELON-1 study, including an exploratory analysis of 3-year PFS per investigator. A total of 1334 patients with stage III or IV cHL were randomized 1:1 to receive 6 cycles of A+AVD (n = 664) or ABVD (n = 670). Interim PET2 was required. At median follow-up of 37 months, 3-year PFS rates were 83.1% with A+AVD and 76.0% with ABVD; 3-year PFS rates in PET2- patients aged <60 years were 87.2% vs 81.0%, respectively. A beneficial trend in PET2+ patients aged <60 years on A+AVD was also observed, with a 3-year PFS rate of 69.2% vs 54.7% with ABVD. The benefit of A+AVD in the intent-to-treat population appeared independent of disease stage and prognostic risk factors. Upon continued follow-up, 78% of patients with peripheral neuropathy on A+AVD had either complete resolution or improvement compared with 83% on ABVD. These data highlight that A+AVD provides a durable efficacy benefit compared with ABVD for frontline stage III/IV cHL, consistent across key subgroups regardless of patient status at PET2, without need for treatment intensification or bleomycin exposure. This trial was registered at www.clinicaltrials.gov as #NCT01712490 (EudraCT no. 2011-005450-60).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Straus DJ, Długosz-Danecka M, Alekseev S, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020. PMID: 31945149. doi:10.1182/blood.2019003127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。